E4512 (sub study A151216)

The purpose of this study is to compare Crizotinib vs observation for patients with a ALK+ Fusion Protein to determine if Crizotinib use results in improved disease-free survival. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC).
Contact phone
Tracy Bellefeuil | 517.364.2835
Contact email
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Trial SubCategory
Non-Small Lung